Company Overview - Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - The main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - For Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - The net profit for the same period was 27.41 million yuan, reflecting a year-on-year decline of 39.23% [1] - The sales gross margin stood at 32.40% [1] Market Position - As of May 6, the company's stock closed at 24.18 yuan, with a rise of 2.76% [1] - The rolling price-to-earnings (PE) ratio is 24.75, while the industry average PE is 48.90 [1][2] - The total market capitalization of the company is 3.81 billion yuan [1] Institutional Holdings - As of Q1 2025, four institutions hold shares in Gongdong Medical, with a total of 14.52 million shares valued at 402 million yuan [1]

第一季度财务报表是否经审计 □是 √否 2025年4月25日，公司第三届董事会审计委员会第十一次会议审议通过了《公司2025年第一季度报 告》，全体委员出席本次会议，无反对票，无弃权票。 2025年4月25日，公司第三届董事会第十五次会议审议通过了《公司2025年第一季度报告》，全体董事 出席本次会议，无反对票，无弃权票。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：605369 证券简称：拱东医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 2025年4月25日，公司第三届监事会第九次会议审议通过了《公司2025年第一季度报告》，全体监事出 席本次会议，无反对票，无弃权票。 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：万元 ...

前十大流通股东累计持有： 11761.61万股，累计占流通股比： 74.65%，较上期变化： -86.69万股。 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1700 | 0.2900 | -41.38 | 0.2600 | | 每股净资产（元） | 11 | 14.95 | -26.42 | 14.38 | | 每股公积金(元) | 4.52 | 6.74 | -32.94 | 6.73 | | 每股未分配利润(元) | 5.13 | 6.66 | -22.97 | 6.34 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.64 | 2.72 | -2.94 | 2.26 | | 净利润(亿元) | 0.27 | 0.45 | -40 | 0.29 | | 净资产收益率(%) | 1.59 | 2.72 | -41.54 | 1.80 | 数据四舍五入，查看更多财务数据> ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 26,447.58 million, a decrease of 2.74% compared to CNY 27,191.85 million in the same period last year[6]. - Net profit attributable to shareholders decreased by 39.23% to CNY 2,741.25 million from CNY 4,510.90 million year-on-year[6]. - Basic earnings per share fell by 41.38% to CNY 0.17 per share, down from CNY 0.29 per share in the previous year[6]. - Net profit for Q1 2025 was ¥27,262,268.82, down 39.6% from ¥45,108,983.69 in Q1 2024[24]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.17, compared to ¥0.29 in Q1 2024[24]. Cash Flow and Investments - The net cash flow from operating activities decreased by 49.96% to CNY 2,055.00 million, compared to CNY 4,106.50 million in the same period last year[6]. - Net cash flow from operating activities for Q1 2025 was ¥20,549,989.34, a decrease of 50.0% from ¥41,065,035.92 in Q1 2024[27]. - The company reported a net cash outflow from investing activities of ¥19,017,455.73 in Q1 2025, compared to a net outflow of ¥24,124,466.30 in Q1 2024[28]. - The company raised ¥87,500,000.00 from financing activities in Q1 2025, compared to a net outflow of ¥1,622,484.19 in Q1 2024[28]. Assets and Liabilities - Total assets increased by 5.88% to CNY 206,613.61 million from CNY 195,134.02 million at the end of the previous year[6]. - As of March 31, 2025, the total assets of the company amounted to RMB 2,066,136,114.73, an increase from RMB 1,951,340,242.04 at the end of 2024, representing a growth of approximately 5.9%[18][20]. - The total liabilities increased to RMB 314,327,094.45 from RMB 233,788,763.79, reflecting a rise of approximately 34.4%[20]. - The company's total current assets reached RMB 990,705,786.20, up from RMB 865,266,163.55, indicating an increase of about 14.5%[19]. - The company reported a total current liability of RMB 237,855,689.24, which is an increase from RMB 182,854,626.05, representing a growth of approximately 30.1%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,909[12]. - Major shareholder施慧勇 holds 50.24% of the shares, amounting to 79,168,600 shares[12]. Other Financial Metrics - The weighted average return on equity decreased by 1.13 percentage points to 1.59% from 2.72% year-on-year[6]. - The decline in net profit was primarily due to losses from the disposal of equity interests and increased expenses related to new projects[9]. - The company reported non-recurring losses totaling CNY -7,331,520.72, significantly impacting overall profitability[8]. - The company's cash and cash equivalents stood at RMB 391,652,497.37, compared to RMB 303,188,874.77, marking a growth of around 29.1%[18]. - The accounts receivable rose to RMB 310,589,250.31 from RMB 260,245,221.85, which is an increase of approximately 19.3%[18]. - The company's non-current assets totaled RMB 1,075,430,328.53, slightly down from RMB 1,086,074,078.49, indicating a decrease of about 1.4%[19]. - The company's retained earnings increased to RMB 808,422,005.56 from RMB 781,009,541.33, showing a growth of approximately 3.5%[20]. - The total equity attributable to the owners of the parent company reached RMB 1,733,959,215.69, up from RMB 1,707,180,400.78, reflecting an increase of about 1.6%[20]. Foreign Exchange and Subsidiaries - The company experienced a foreign exchange loss of ¥149,994.35 in Q1 2025, compared to a gain of ¥490,563.19 in Q1 2024[28]. - The company did not report any net profit from subsidiaries prior to the merger in Q1 2025, consistent with Q1 2024[25].

Company Overview - Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables, with main products including medical testing, blood collection, sampling, medical care, and drug packaging [1]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.115 billion yuan, representing a year-on-year increase of 14.37% [1]. - The net profit for the same period was 172 million yuan, showing a significant year-on-year growth of 57.28% [1]. - The sales gross margin stood at 32.79% [1]. Market Position - As of April 23, the company's stock closed at 25.24 yuan, with a PE ratio of 23.17, marking a new low in 13 days [1]. - The total market capitalization of the company is 3.977 billion yuan [1]. - In comparison to the medical device industry, which has an average PE ratio of 47.57 and a median of 30.28, Gongdong Medical ranks 55th in the industry [2]. Shareholder Information - As of March 31, 2025, the number of shareholders for Gongdong Medical reached 8,909, an increase of 735 from the previous count [1]. - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1].

拱东医疗 2025042220250416 摘要 • 公司管理层致力于完成全年销售目标，海外市场已在美国、欧洲和东南亚 等地布局，未来几年有望贡献增长，但需关注各地关税政策变化带来的影 响。 • 中国模具企业在全球仍具竞争力，产业链集群效应和专业分工体系降低了 成本，但关税成本影响利润，公司汇率管控以中性原则应对波动。 • TPI 工厂 2024 年毛利率提升至 27-28%，净利率超 10%，主要受益于产 能扩大和销量提升，但人工成本仍是主要成本因素，未来扩产计划需考虑 成本因素。 • TPR 的 2024 年产能利用率为 35%-40%，预计 2025 年提升至 50%左右， 具体进度取决于客户订单转移和新增订单情况，需动态调整。 • GPI 的 2024 年毛利率和净利润率显著提升，受益于提前布局美国市场， 报价体系与中国不同，确保 ILPRA 毛利率稳定，预计 2025 年营收增长超 10%。 • 国内市场受大环境影响增长压力较大，公司通过调整价格、提升订单规模 效应、优化生产成本来增加盈利能力，并积极扩展新领域，资本开支集中 在 88 号二期项目和郑州子公司生产基地。 • 公司通过美国 TPR 工厂 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 拱东医疗(605369) 投资评级 上次评级 | 执业编号：S1500523080002 | | | --- | --- | | [Table_Author] 唐爱金 邮 | 医药行业首席分析师 箱：tangaijin@cindasc.com | 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 境外收入增长 27%，全球化布局，增长可期 [Table_ReportDate] 2025 年 04 月 22 日 [Table_S 事件：公司发布 ummary] 2024 年年报，2024 年实现营业收入 11.15 亿元（yoy+ 14.37%），归母净利润 1.72 亿元（yoy+57.28%），扣非归母净利润 1.68 亿元（ yoy+56.18% ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 拱东医疗(605369) 投资评级 上次评级 | 执业编号：S1500523080002 | | | --- | --- | | [Table_Author] 唐爱金 邮 | 医药行业首席分析师 箱：tangaijin@cindasc.com | 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 境外收入增长 27%，全球化布局，增长可期 [Table_S 事件：公司发布 ummary] 2024 年年报，2024 年实现营业收入 11.15 亿元（yoy+ 14.37%），归母净利润 1.72 亿元（yoy+57.28%），扣非归母净利润 1.68 亿元（ yoy+56.18% ） ， 经 营 活 动 产 生 的 现 金 流 量 净 额 2.1 亿 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、会计政策变更对公司的影响 本次会计政策变更是公司根据财政部相关规定和要求进行的变更，执行变更后的会计政策能够客观、公 允地反映公司的财务状况和经营成果，符合相关法律法规的规定及公司实际情况。本次会计政策变更不 会对公司财务状况、经营成果和现金流量产生重大影响，不存在损害公司及股东利益的情况。 特此公告。 浙江拱东医疗器械股份有限公司董事会 2025年4月22日 证券代码：605369 证券简称：拱东医疗 公告编号：2025-008 浙江拱东医疗器械股份有限公司 第三届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江拱东医疗器械股份有限公司（以下简称"公司"）第三届董事会第十四次会议于2025年4月21日在公 司三楼会议室以现场结合通讯表决方式召开。会议通知已于2025年4月10日通过专人、邮件送达及电 话、微信通知等方式发出。本次会议由董事长施慧勇先生主持，会议应出席董事7人，实际出席董事7人 （其中以通讯表决方式出席 ...

年报显示，拱东医疗2024年在研发方面的投入达5304.55万元，占营收4.76%，新增发明专利1项、实用 新型专利3项，国内I类医疗器械备案证书2项，并取得欧盟IVDR、MDR等多项认证。通过AI驱动的柔 性生产线、数字化工艺管理平台，公司实现生产全流程自动化，产品缺陷率显著降低。例如，通过对血 液收集类耗材自动化生产线的引入，使该产线的效率提升30%，废品率下降15%。 全球老龄化与医疗基建扩张推动低值医用耗材需求增长，国内集采政策则加速行业集中度提升。拱东医 疗凭借9000余种规格的产品矩阵，一方面重点聚焦大客户定制业务，加强对全球体外诊断行业头部客户 的业务开拓力度，一方面通过中标集采巩固国内市场份额。公司表示，未来将深化"技术创新+产能扩 张"双轮驱动，布局生物可降解材料、智能包装等新兴领域，强化全球供应链韧性。 2024年，拱东医疗海外业务表现抢眼，销售额达6.76亿元，同比增长27.52%，占总营收比重超60%。公 司通过美国子公司TPI加速全球化布局，深化与IDEXX、Medline等国际头部客户的合作，强化了在欧美 市场的品牌影响力。TPI全年营收同比增长41.37%，成为公司拓展海外高端耗 ...